Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
The latest update is out from Biora Therapeutics ( (BIOR) ).
Biora Therapeutics has filed for Chapter 11 bankruptcy to facilitate a sale process aimed at strengthening its balance sheet and continuing product development. The company has secured up to $10.25 million in debtor-in-possession financing to support ongoing operations and intends to use a competitive bidding process to maximize value for its stakeholders, with the expectation of emerging quickly to focus on its core platforms.
More about Biora Therapeutics
Biora Therapeutics is a clinical-stage biotech company developing smart pill-based therapeutic platforms, including the NaviCap platform for colon-targeted treatment of IBD and the BioJet platform for needle-free oral delivery of large molecules.
YTD Price Performance: -96.74%
Average Trading Volume: 134,039
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.99M
See more insights into BIOR stock on TipRanks’ Stock Analysis page.
